國立虎尾科技大學 |

Inflammatory Pathways in Diabetes = Biomarkers and Clinical Correlates /

Record Type:	Language materials, printed : Monograph/item
Title/Author:	Inflammatory Pathways in Diabetes/ edited by Michael Pugia.
Reminder of title:	Biomarkers and Clinical Correlates /
other author:	Pugia, Michael.
Description:	XVI, 219 p. 33 illus., 18 illus. in color.online resource. :
Contained By:	Springer Nature eBook
Subject:	Immunology. -
Online resource:	https://doi.org/10.1007/978-3-319-21927-1
ISBN:	9783319219271

Inflammatory Pathways in Diabetes = Biomarkers and Clinical Correlates /
Inflammatory Pathways in DiabetesBiomarkers and Clinical Correlates /[electronic resource] :edited by Michael Pugia. - 1st ed. 2015. - XVI, 219 p. 33 illus., 18 illus. in color.online resource. - Progress in Inflammation Research,0379-0363. - Progress in Inflammation Research,.

Part 1. Introduction -- 1. Impact of inflammation and the innate immunity response in obesity mediated diabetes (lit review) -- Part 2. Impact of complement on diabetic disease -- 2. Complement and Complement Regulatory Proteins in Diabetes -- Part 3. Role of C terminal fragment of adiponectin receptor in inhibition of insulin degradation -- 3. Development of adiponectin receptor C terminal fragment bioassays -- 4. Protease inhibition and biological distribution of the C terminal fragment of adiponectin receptor -- 5. Cell & biological models for the C terminal fragment of adiponectin receptor -- 6. C-Terminal fragment of adiponectin receptor clinical correlations -- Part 4. Uristatin assay for prediction of renal and other clinical events -- 7. Uristatin immunoassay usage in glomerular nephritis assessment -- 8. Acute Response of Uristatin in Surgery -- 9. Cardiovascular and metabolic syndrome impact on uristatin -- 10. Uristatin anti-inflammatory cellular signaling -- Part 5. Summary -- 11. Overview of progress in new markers for diabetes inflammation (Literatue Review).

This book discusses recent advances in new anti- and pro-inflammatory pathways in diabetic disease, and identifies new diagnostic immunological methods that offer potential companion diagnostics for diabetic diseases. New methods in proteomics, mass spectroscopy, immunological assay design, measurement of cellular signal transduction and protease inhibition are used to clarify new biochemical pathways. Biomarker validation in animal models and correlations in humans for diagnostic clinical trials shed new light on the impact of diabetic diseases. The book reviews current understanding of inflammatory pathways in the pathophysiology of insulin resistance, metabolic syndrome, nephritis and other diabetic inflammatory conditions, and is the first to describe the impact of novel adipokines, protease inhibitors and complement markers. By presenting new methodologies for biomarker discovery, it provides a valuable resource for researchers studying clinical diagnosis, drug development, bio-analytical chemistry, proteomics and biochemistry. It is also useful for those conducting clinical and biological studies for targeted drug development. The methodologies and approaches can be applied to other markers, and the information will be helpful in the preparation of research grant applications.

ISBN: 9783319219271

Standard No.: 10.1007/978-3-319-21927-1doiSubjects--Topical Terms:

592892
Immunology.

LC Class. No.: QR180-189.5

Dewey Class. No.: 616.079

Inflammatory Pathways in Diabetes = Biomarkers and Clinical Correlates /
LDR:03848nam a22004095i 4500 001 962822
003 DE-He213
005 20200703150308.0
007 cr nn 008mamaa
008 201211s2015 gw | s |||| 0|eng d
020 $a 9783319219271 $9 978-3-319-21927-1
024 7 $a 10.1007/978-3-319-21927-1 $2 doi
035 $a 978-3-319-21927-1
050 4 $a QR180-189.5
072 7 $a MJCM $2 bicssc
072 7 $a MED044000 $2 bisacsh
072 7 $a MJCM $2 thema
082 0 4 $a 616.079 $2 23
245 1 0 $a Inflammatory Pathways in Diabetes $h [electronic resource] : $b Biomarkers and Clinical Correlates / $c edited by Michael Pugia.
250 $a 1st ed. 2015.
264 1 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2015.
300 $a XVI, 219 p. 33 illus., 18 illus. in color. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
490 1 $a Progress in Inflammation Research, $x 0379-0363
505 0 $a Part 1. Introduction -- 1. Impact of inflammation and the innate immunity response in obesity mediated diabetes (lit review) -- Part 2. Impact of complement on diabetic disease -- 2. Complement and Complement Regulatory Proteins in Diabetes -- Part 3. Role of C terminal fragment of adiponectin receptor in inhibition of insulin degradation -- 3. Development of adiponectin receptor C terminal fragment bioassays -- 4. Protease inhibition and biological distribution of the C terminal fragment of adiponectin receptor -- 5. Cell & biological models for the C terminal fragment of adiponectin receptor -- 6. C-Terminal fragment of adiponectin receptor clinical correlations -- Part 4. Uristatin assay for prediction of renal and other clinical events -- 7. Uristatin immunoassay usage in glomerular nephritis assessment -- 8. Acute Response of Uristatin in Surgery -- 9. Cardiovascular and metabolic syndrome impact on uristatin -- 10. Uristatin anti-inflammatory cellular signaling -- Part 5. Summary -- 11. Overview of progress in new markers for diabetes inflammation (Literatue Review).
520 $a This book discusses recent advances in new anti- and pro-inflammatory pathways in diabetic disease, and identifies new diagnostic immunological methods that offer potential companion diagnostics for diabetic diseases. New methods in proteomics, mass spectroscopy, immunological assay design, measurement of cellular signal transduction and protease inhibition are used to clarify new biochemical pathways. Biomarker validation in animal models and correlations in humans for diagnostic clinical trials shed new light on the impact of diabetic diseases. The book reviews current understanding of inflammatory pathways in the pathophysiology of insulin resistance, metabolic syndrome, nephritis and other diabetic inflammatory conditions, and is the first to describe the impact of novel adipokines, protease inhibitors and complement markers. By presenting new methodologies for biomarker discovery, it provides a valuable resource for researchers studying clinical diagnosis, drug development, bio-analytical chemistry, proteomics and biochemistry. It is also useful for those conducting clinical and biological studies for targeted drug development. The methodologies and approaches can be applied to other markers, and the information will be helpful in the preparation of research grant applications.
650 0 $a Immunology. $3 592892
650 0 $a Diabetes. $3 582755
650 0 $a Pharmacology. $3 583819
650 0 $a Metabolic diseases. $3 1253620
650 0 $a Biochemistry. $3 582831
650 2 4 $a Pharmacology/Toxicology. $3 593882
650 2 4 $a Metabolic Diseases. $3 593967
650 2 4 $a Biochemistry, general. $3 593881
700 1 $a Pugia, Michael. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1068912
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9783319219288
776 0 8 $i Printed edition: $z 9783319219264
776 0 8 $i Printed edition: $z 9783319372815
830 0 $a Progress in Inflammation Research, $x 0379-0363 $3 1257722
856 4 0 $u https://doi.org/10.1007/978-3-319-21927-1
912 $a ZDB-2-SBL
912 $a ZDB-2-SXB
950 $a Biomedical and Life Sciences (SpringerNature-11642)
950 $a Biomedical and Life Sciences (R0) (SpringerNature-43708)